Sanofi SA (EPA:SAN)‘s stock had its “neutral” rating restated by J P Morgan Chase & Co in a note issued to investors on Thursday.

A number of other research firms also recently issued reports on SAN. HSBC Holdings plc set a €81.00 ($95.29) price target on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Tuesday, September 12th. Kepler Capital Markets set a €90.00 ($105.88) price target on shares of Sanofi SA and gave the company a “buy” rating in a research report on Thursday, September 7th. BNP Paribas set a €83.00 ($97.65) price target on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Jefferies Group LLC set a €87.00 ($102.35) price target on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Thursday, August 24th. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price target on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of €88.12 ($103.67).

ILLEGAL ACTIVITY NOTICE: “Sanofi SA (SAN) Stock Rating Reaffirmed by J P Morgan Chase & Co” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/sanofi-sa-san-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.